Opportunity Information: Apply for HT9425 23 PCRP IDA
The DoD Prostate Cancer Research Program (PCRP) FY23 Idea Development Award is built to fund fresh, high-risk, high-reward concepts in prostate cancer research that could meaningfully push the field forward. The central expectation is that the project is truly innovative, meaning it introduces a new way of thinking, challenges an established assumption, applies a creative method to a persistent problem, or leverages a special population or dataset in a novel way. Proposals that mainly extend previously published work in a straightforward, incremental manner are not considered a strong fit. The opportunity also signals strong interest in multidisciplinary projects and data science driven approaches, reflecting the program's push for teams that combine different skill sets to tackle complex prostate cancer questions.
A second core requirement is impact. Applicants must clearly connect their idea to at least one of the FY23 PCRP Overarching Challenges and explain how the work could provide a solution or a credible path toward one. Reviewers are looking for a convincing description of how the project could matter in both the near term and the longer term, whether by advancing fundamental understanding, improving diagnosis or risk stratification, shaping treatment decisions, or ultimately improving patient outcomes. In other words, novelty alone is not enough; the proposal needs a strong rationale for why the idea, if it works, could significantly advance prostate cancer research and/or patient care.
Preliminary data are encouraged but not required, which is important because it lowers the barrier for genuinely new ideas that may not yet have extensive supporting results. If preliminary findings are included, they should come from the PI's lab or from members of the project team, and they can be unpublished. Even without preliminary data, the application still needs to rest on a sound scientific rationale grounded in logical reasoning and a careful reading of existing literature. The announcement also highlights practical expectations that strengthen rigor and translational value, such as authenticating cell lines, applying statistical rigor in animal studies and epidemiology, building in experiments that test clinical relevance, and validating findings in patient cohorts when appropriate. If the project depends on specialized resources (for example, unique biospecimens, databases, or platforms), the program encourages letters of support to document access and availability.
The mechanism includes a specific New Investigator category aimed at researchers early in their independent careers. This category is designed to help launch new faculty or investigators building independence, but it comes with a key condition: applicants must include at least one collaborator with demonstrated prostate cancer expertise, shown through a track record of funding and publications. The application should explain how the collaboration will work, why it is likely to succeed, and how it strengthens the science by filling gaps in the PI's experience. A letter of collaboration describing the collaborator's role is strongly encouraged, and New Investigator applicants must meet the eligibility requirements described in the full announcement.
Team science is explicitly supported. Multidisciplinary and multi-institutional projects are allowed, but they must include a clear coordination plan explaining how team members will communicate, share data, manage progress, and integrate results across sites. For multi-institutional proposals, an intellectual property plan is also required to prevent institutional barriers from undermining collaboration and to address ownership and material transfer issues upfront.
Human subjects research is permitted, but clinical trials are not allowed. The program draws a bright line between observational clinical research (which is allowed) and clinical trials (which are not). In practice, that means studies using patient data or specimens, biomarker and imaging research, mechanism of disease studies, health disparities work, epidemiology, behavioral studies, and outcomes/health services research can be acceptable as long as they do not prospectively assign participants to an intervention to measure its effects. Correlative studies tied to an existing clinical trial are particularly encouraged, which is a way to extract additional scientific value from trials that are already underway without launching a new interventional study under this award. Any prospective human research must be no greater than minimal risk as determined by the IRB and DoD human research oversight.
Regulatory oversight requirements are a major operational consideration. DoD funded work involving human data, specimens, or subjects requires review not only by a local IRB/ethics committee but also by the USAMRDC Office of Human and Animal Research Oversight (OHARO), specifically the Office of Human Research Oversight (OHRO), before the study can begin. Local IRB approval is not required at the time of application, but it is required before OHRO review, and the DoD review can take up to around three months once complete documentation is submitted. For multi-site, non-exempt cooperative research within the U.S., applicants must plan for a single IRB arrangement under federal regulations, identifying the lead institution responsible for the master protocol and consent materials and serving as the main regulatory point of contact.
Animal research is also allowed, but it must undergo both local IACUC review and additional DoD level review through ACURO (the Animal Care and Use Review Office) before work starts. IACUC approval is not required at submission, but investigators should plan for DoD review timelines, commonly three to four months. The program strongly emphasizes reproducibility and transparent reporting for preclinical studies, pointing applicants to widely used rigor standards such as randomization, blinding, sample size estimation, and careful data handling, and encourages alignment with ARRIVE guidelines for animal research reporting.
From a funding and administrative standpoint, awards are issued as assistance agreements, meaning they may be grants or cooperative agreements depending on how much substantial involvement the DoD anticipates having during performance. If the agency expects minimal involvement, it is typically a grant; if collaboration or ongoing programmatic involvement is expected, it may be a cooperative agreement with those roles spelled out in the award. The direct cost budget for the full performance period is expected not to exceed $900,000. The program planned roughly $36 million total to support about 25 awards, with awards anticipated no later than September 30, 2024, and FY23 funds expected to remain available for use through September 30, 2029 (which matters for the government's obligation and spending window, not necessarily the length of each project).
Strategically, the opportunity aligns with broader DoD and congressional interest in accelerating progress for advanced and recurrent disease, including recommendations from the Metastatic Cancer Task Force, which applicants are encouraged to consult when shaping ideas that fit the FY23 priorities. The DoD also encourages collaborations between military or Veterans institutions and non-military partners, highlighting the value of combining infrastructure, expertise, and access to unique patient populations to generate findings that matter to Service members, Veterans, and the general public.Apply for HT9425 23 PCRP IDA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Apr 03, 2023.
- Applicants must submit their applications by Jul 20, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 25 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): DoD Prostate Cancer Research Program (PCRP) FY23 Idea Development Award
1. What is the goal of the FY23 PCRP Idea Development Award?
The award is intended to fund fresh, high-risk, high-reward prostate cancer research ideas that could meaningfully move the field forward. The program is looking for concepts that are truly innovative and have a clear path to impact.
2. What does the program mean by "truly innovative"?
"Truly innovative" means the project introduces a new way of thinking, challenges an established assumption, applies a creative method to a persistent problem, or leverages a special population or dataset in a novel way. Projects that mainly extend previously published work in a straightforward, incremental way are not considered a strong fit for this mechanism.
3. Are multidisciplinary projects encouraged?
Yes. The opportunity signals strong interest in multidisciplinary projects and data science driven approaches, reflecting a preference for teams that combine different skill sets to tackle complex prostate cancer questions.
4. Is there a required focus on "impact" as well as innovation?
Yes. Innovation alone is not enough. Applicants must connect the proposed work to at least one of the FY23 PCRP Overarching Challenges and explain how the project could provide a solution or a credible path toward one, with a convincing case for near-term and long-term importance.
5. What kinds of impact are reviewers looking for?
The program describes impact in terms of advancing fundamental understanding, improving diagnosis or risk stratification, shaping treatment decisions, and/or ultimately improving patient outcomes. Applicants are expected to explain why the idea could significantly advance prostate cancer research and/or patient care if successful.
6. Is preliminary data required?
No. Preliminary data are encouraged but not required, which is meant to lower the barrier for genuinely new concepts that may not yet have extensive supporting results.
7. If preliminary data are included, are there limits on what can be used?
Yes. If preliminary findings are included, they should come from the PI's lab or from members of the project team, and they can be unpublished.
8. If an application has no preliminary data, what is expected instead?
The application still needs a sound scientific rationale grounded in logical reasoning and a careful reading of existing literature.
9. What rigor and reproducibility expectations are highlighted for preclinical or translational work?
The announcement emphasizes practices that strengthen rigor and translational value, including authenticating cell lines, applying statistical rigor in animal studies and epidemiology, building in experiments that test clinical relevance, and validating findings in patient cohorts when appropriate.
10. Are letters of support recommended for access to specialized resources?
Yes. If the project depends on specialized resources such as unique biospecimens, databases, or platforms, the program encourages letters of support to document access and availability.
11. Is there a New Investigator category?
Yes. The mechanism includes a New Investigator category aimed at researchers early in their independent careers and intended to help launch investigators building independence.
12. What is a key collaboration requirement for New Investigators?
New Investigator applicants must include at least one collaborator with demonstrated prostate cancer expertise, shown through a track record of funding and publications.
13. What should New Investigator applications explain about the collaboration?
The application should explain how the collaboration will work, why it is likely to succeed, and how it strengthens the science by filling gaps in the PI's experience.
14. Are letters of collaboration expected for New Investigator applications?
A letter of collaboration describing the collaborator's role is strongly encouraged.
15. Are multi-institutional projects allowed?
Yes. Team science is explicitly supported, and multidisciplinary and multi-institutional projects are allowed.
16. What coordination details are expected for team-based or multi-site projects?
Applications should include a clear coordination plan describing how team members will communicate, share data, manage progress, and integrate results across sites.
17. Is an intellectual property (IP) plan required for multi-institutional proposals?
Yes. For multi-institutional proposals, an IP plan is required to address ownership and material transfer issues up front and to reduce the risk that institutional barriers interfere with collaboration.
18. Is human subjects research allowed?
Yes. Human subjects research is permitted under this mechanism.
19. Are clinical trials allowed?
No. Clinical trials are not allowed. The program distinguishes allowed observational clinical research from prohibited clinical trials.
20. What types of human research are described as acceptable?
Examples described as potentially acceptable include studies using patient data or specimens, biomarker and imaging research, mechanism of disease studies, health disparities research, epidemiology, behavioral studies, and outcomes/health services research, as long as they do not prospectively assign participants to an intervention to measure its effects.
21. Are correlative studies related to existing clinical trials allowed?
Yes. Correlative studies tied to an existing clinical trial are particularly encouraged as a way to generate additional scientific value from trials already underway without launching a new interventional study under this award.
22. What risk level is allowed for prospective human research?
Any prospective human research must be no greater than minimal risk as determined by the IRB and DoD human research oversight.
23. What human research oversight is required for DoD-funded work?
DoD-funded work involving human data, specimens, or subjects requires review by both a local IRB/ethics committee and the USAMRDC Office of Human and Animal Research Oversight (OHARO), specifically the Office of Human Research Oversight (OHRO), before the study can begin.
24. Is local IRB approval required at the time of application?
No. Local IRB approval is not required at the time of application, but it is required before OHRO review can occur.
25. How long can the DoD human research oversight review take?
The DoD OHRO review can take up to around three months once complete documentation is submitted.
26. What is required for multi-site, non-exempt cooperative human research in the U.S.?
Applicants must plan for a single IRB arrangement under federal regulations. The application should identify the lead institution responsible for the master protocol and consent materials and serving as the main regulatory point of contact.
27. Is animal research allowed?
Yes. Animal research is allowed under this mechanism.
28. What oversight is required for animal research?
Animal studies must undergo both local IACUC review and additional DoD-level review through ACURO (the Animal Care and Use Review Office) before work starts.
29. Is IACUC approval required at the time of application?
No. IACUC approval is not required at submission, but applicants should plan for DoD review timelines before work can begin.
30. How long can the DoD animal research review take?
Applicants are advised to plan for DoD animal review timelines, commonly three to four months.
31. What reproducibility practices are emphasized for animal studies?
The program emphasizes transparent reporting and widely used rigor standards such as randomization, blinding, sample size estimation, and careful data handling, and it encourages alignment with ARRIVE guidelines for animal research reporting.
32. What type of award instrument will be used?
Awards are issued as assistance agreements, meaning they may be grants or cooperative agreements depending on the level of substantial involvement the DoD anticipates during performance.
33. What determines whether the award is a grant or a cooperative agreement?
If the agency expects minimal involvement, the award is typically a grant. If ongoing collaboration or programmatic involvement is expected, it may be a cooperative agreement, with those roles spelled out in the award.
34. What is the expected maximum budget?
The direct cost budget for the full performance period is expected not to exceed $900,000.
35. How many awards and how much total funding are planned?
The program planned roughly $36 million total to support about 25 awards.
36. When are awards anticipated to be made?
Awards are anticipated no later than September 30, 2024.
37. How long are FY23 funds expected to remain available for use?
FY23 funds are expected to remain available for use through September 30, 2029. This relates to the government's obligation and spending window, not necessarily the length of each project.
38. How does this opportunity align with broader DoD priorities?
The opportunity aligns with DoD and congressional interest in accelerating progress for advanced and recurrent disease, including recommendations from the Metastatic Cancer Task Force, which applicants are encouraged to consult when shaping ideas that fit the FY23 priorities.
39. Does the program encourage partnerships with military or Veterans institutions?
Yes. The DoD encourages collaborations between military or Veterans institutions and non-military partners, emphasizing the value of combining infrastructure, expertise, and access to unique patient populations to generate findings relevant to Service members, Veterans, and the general public.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: OSERS: OSEP: Personnel Development to Improve Services and Results for Children with Disabilities--Preparation of Early Intervention and Special Education Personnel Serving Children with Disabilities who have High-Intensity Needs, ALN 84.325K
Previous opportunity: DOD Peer Reviewed Alzheimer’s, Transforming Care Award
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HT9425 23 PCRP IDA
Applicants also applied for:
Applicants who have applied for this opportunity (HT9425 23 PCRP IDA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Prostate Cancer, Physician Research Award Apply for HT9425 23 PCRP PRA Funding Number: HT9425 23 PCRP PRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Exploration-Hypothesis Development Award Apply for HT9425 23 PCRP EHDA Funding Number: HT9425 23 PCRP EHDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Early Investigator Research Award Apply for HT9425 23 PCRP EIRA Funding Number: HT9425 23 PCRP EIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Rehabilitation Engineering Research Centers (RERC) Program: RERC on Universal Access to Information and Communication Technology Apply for HHS 2023 ACL NIDILRR REGE 0097 Funding Number: HHS 2023 ACL NIDILRR REGE 0097 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $925,000 |
| DoD Peer Reviewed Cancer, Career Development Award Apply for HT9425 23 PRCRP CDA Funding Number: HT9425 23 PRCRP CDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Advancing Cancer Care through Clinical Trials Award Apply for HT9425 23 PRCRP ACCCT Funding Number: HT9425 23 PRCRP ACCCT Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Impact Award Apply for HT9425 23 PRCRP IPA Funding Number: HT9425 23 PRCRP IPA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Idea Award Apply for HT9425 23 PRCRP IA Funding Number: HT9425 23 PRCRP IA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Translational Team Science Award Apply for HT9425 23 PRCRP TTSA Funding Number: HT9425 23 PRCRP TTSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Cancer, Patient Well-Being and Survivorship Award Apply for HT9425 23 PRCRP PWSA Funding Number: HT9425 23 PRCRP PWSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOE Traineeship in Accelerator Science & Technology Apply for DE FOA 0003025 Funding Number: DE FOA 0003025 Agency: Department of Energy - Office of Science, Office of Science Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Center of Excellence on New Mobility and Automated Vehicles Apply for 693JJ323NF00008 Funding Number: 693JJ323NF00008 Agency: Department of Transportation, DOT Federal Highway Administration Category: Science and Technology and other Research and Development Funding Amount: $7,500,000 |
| DoD Tick-Borne Research Program Idea Development Award Apply for HT9425 23 TBDRP IDA Funding Number: HT9425 23 TBDRP IDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Rehabilitation Research and Training Center (RRTC) on Disability Statistics and Demographics Apply for HHS 2023 ACL NIDILRR RTGE 0028 Funding Number: HHS 2023 ACL NIDILRR RTGE 0028 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $875,000 |
| DoD Tick-Borne Disease Research Program Therapeutic/Diagnostic Research Award Apply for HT9425 23 TBDRP TDRA Funding Number: HT9425 23 TBDRP TDRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Interfacial Engineering Apply for PD 23 1417 Funding Number: PD 23 1417 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Nanoscale Interactions Apply for PD 23 1179 Funding Number: PD 23 1179 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Environmental Sustainability Apply for PD 23 7643 Funding Number: PD 23 7643 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CyberCorps(R) Scholarship for Service Apply for 23 574 Funding Number: 23 574 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Standards Coordination Office Curricula Development Cooperative Agreement Program (SCO CD CAP) Apply for 2023 NIST SCOCD 01 Funding Number: 2023 NIST SCOCD 01 Agency: Department of Commerce, National Institute of Standards and Technology Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HT9425 23 PCRP IDA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.